Literature DB >> 18802361

Comparative study of cluster and conventional immunotherapy schedules with dermatophagoides pteronyssinus in the treatment of persistent allergic rhinitis.

Luo Zhang1, Chengshuo Wang, Demin Han, Xiangdong Wang, Yan Zhao, Jianhui Liu.   

Abstract

BACKGROUND AND OBJECTIVES: Allergy to house dust mite is one of the most common causes of allergic rhinitis (AR) in China. We sought to compare the efficacy and safety of a 6-week cluster schedule of specific immunotherapy with that of a 14-week conventional schedule for the treatment of subjects with persistent AR.
METHODS: The trial was a prospective and randomized study involving 96 patients with persistent AR, aged 14-60 years, who were allergic to Dermatophagoides pteronyssinus. While 48 patients were randomly assigned to the cluster schedule reaching the maintenance dose within 6 weeks, the other 48 were randomly assigned to the conventional schedule reaching the maintenance dose within 14 weeks. Eighty-nine patients completed a 1-year treatment course. While kinetic changes in clinical efficacy and adverse reactions were observed during the treatment, quality of life, cutaneous reactivity and serum-specific immunoglobulin E to Dermatophagoides pteronyssinus were measured before and after treatment.
RESULTS: The cluster schedule reduced the time to reach the maintenance dose by 57% and caused mild systemic adverse reactions after 1.0% of injections (6.7% of patients), with no differences in comparison with the conventional schedule. Cluster specific immunotherapy led to decreases in clinical symptoms and earlier use of medication than did the conventional schedule. Similar improvements in quality of life and reduced cutaneous reactivity without significant changes in specific immunoglobulin E were observed in both groups after 1 year.
CONCLUSIONS: The cluster schedule is a safe alternative to the conventional schedule with the advantage of achieving clinical effectiveness sooner. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18802361     DOI: 10.1159/000155747

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  14 in total

1.  Safety aspects of subcutaneous immunotherapy with multiple allergens--a retrospective analysis on polysensitized patients.

Authors:  C Barth; F Anero; O Pfaar; L Klimek; K Hörmann; B A Stuck
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-05-09       Impact factor: 2.503

Review 2.  Chinese Society of Allergy Guidelines for Diagnosis and Treatment of Allergic Rhinitis.

Authors:  Lei Cheng; Jianjun Chen; Qingling Fu; Shaoheng He; Huabin Li; Zheng Liu; Guolin Tan; Zezhang Tao; Dehui Wang; Weiping Wen; Rui Xu; Yu Xu; Qintai Yang; Chonghua Zhang; Gehua Zhang; Ruxin Zhang; Yuan Zhang; Bing Zhou; Dongdong Zhu; Luquan Chen; Xinyan Cui; Yuqin Deng; Zhiqiang Guo; Zhenxiao Huang; Zizhen Huang; Houyong Li; Jingyun Li; Wenting Li; Yanqing Li; Lin Xi; Hongfei Lou; Meiping Lu; Yuhui Ouyang; Wendan Shi; Xiaoyao Tao; Huiqin Tian; Chengshuo Wang; Min Wang; Nan Wang; Xiangdong Wang; Hui Xie; Shaoqing Yu; Renwu Zhao; Ming Zheng; Han Zhou; Luping Zhu; Luo Zhang
Journal:  Allergy Asthma Immunol Res       Date:  2018-07       Impact factor: 5.764

Review 3.  Immunotherapy in all aspects.

Authors:  Deniz Hanci; Ethem Şahin; Nuray Bayar Muluk; Cemal Cingi
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-02-12       Impact factor: 2.503

Review 4.  Chinese Guideline on allergen immunotherapy for allergic rhinitis.

Authors:  Yixiao Bao; Jianjun Chen; Lei Cheng; Yinshi Guo; Suling Hong; Weijia Kong; He Lai; Houyong Li; Huabin Li; Jing Li; Tianying Li; Xiaoping Lin; Shixi Liu; Zheng Liu; Hongfei Lou; Juan Meng; Qianhui Qiu; Kunling Shen; Wei Tang; Zezhang Tao; Chengshuo Wang; Xiangdong Wang; Qingyu Wei; Li Xiang; Hua Xie; Yu Xu; Gehua Zhang; Yuan Zhang; Yiwu Zheng; Yuxiang Zhi; Dehua Chen; Haiyu Hong; Quansheng Li; Lin Liu; Yifan Meng; Nan Wang; Yihui Wang; Yue Zhou; Luo Zhang
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

Review 5.  Accelerated immunotherapy schedules.

Authors:  Christopher W Calabria
Journal:  Curr Allergy Asthma Rep       Date:  2013-08       Impact factor: 4.806

Review 6.  Cluster subcutaneous allergen specific immunotherapy for the treatment of allergic rhinitis: a systematic review and meta-analysis.

Authors:  Shaoyan Feng; Ying Xu; Renqiang Ma; Yueqi Sun; Xi Luo; Huabin Li
Journal:  PLoS One       Date:  2014-01-28       Impact factor: 3.240

7.  A novel and well tolerated mite allergoid subcutaneous immunotherapy: evidence of clinical and immunologic efficacy.

Authors:  Albert Roger; Nathalie Depreux; Yani Jurgens; Matthew D Heath; Gloria Garcia; Murray A Skinner
Journal:  Immun Inflamm Dis       Date:  2014-05-29

8.  A high polymerized grass pollen extract is efficacious and safe in a randomized double-blind, placebo-controlled study using a novel up-dosing cluster-protocol.

Authors:  L Klimek; J Uhlig; R Mösges; K Rettig; O Pfaar
Journal:  Allergy       Date:  2014-10-06       Impact factor: 13.146

9.  Cloning, bioinformatics analysis, and expression of the dust mite allergen Der f 5 of Dermatophagoides farinae.

Authors:  Yubao Cui; Ying Zhou; Guifang Ma; Li Yang; Yungang Wang; Weihong Shi
Journal:  Braz J Med Biol Res       Date:  2012-05-17       Impact factor: 2.590

10.  Trends in Specific Immunotherapy for Allergic Rhinitis: A Survey of Chinese ENT Specialists.

Authors:  Han Zhou; Qi-Lei Tao; Jun-Min Wei; Geng Xu; Lei Cheng
Journal:  Allergy Asthma Immunol Res       Date:  2014-02-13       Impact factor: 5.764

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.